Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 10/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033257 | 0.86 | ALDH1A1 (0.48) | SMN1; SMN2TACR1ALDH1A1HTTCCR2 | |
| SCHEMBL3034263 | 0.83 | PPARG (0.53) | ALDH1A1HTTKCNH2 | |
| SCHEMBL13243602 | 0.82 | ALDH1A1 (0.46) | SMN1; SMN2TACR1ALDH1A1HTTCCR2 | |
| SCHEMBL3033033 | 0.82 | CYP3A4 (0.49) | TACR1ALDH1A1HTTCCR2FAAH | |
| SCHEMBL3033014 | 0.81 | CCR2 (0.49) | SMN1; SMN2TACR1MEN1ALDH1A1KMT2A | |
| SCHEMBL14222033 | 0.79 | MAPT (0.48) | MEN1MAPTKMT2ACCR2FAAH | |
| SCHEMBL13222917 | 0.79 | CCR2 (0.47) | ALDH1A1CCR2KCNH2 | |
| SCHEMBL3783464 | 0.78 | CCR2 (0.43) | ALDH1A1CCR2KCNH2 | |
| SCHEMBL3029686 | 0.77 | TSHR (0.43) | SMN1; SMN2ALDH1A1NPSR1CCR2KCNH2 | |
| SCHEMBL3034310 | 0.77 | KMT2A (0.48) | SMN1; SMN2MEN1ALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008045564-A2 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | SMN1; SMN2 3522/4885TACR1 539/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.